Sustained CD4 responses after virological failure of protease inhibitor-containing therapy.
This article explores current controversies related to 'discordant' responses to antiviral therapy, that is to say, patients with a sustained CD4 cell response despite virological failure. Observational clinical data of patients receiving protease inhibitor-based therapy who had a sustained CD4 cell count even with incomplete viral suppression will be presented, as well as possible mechanisms and clinical implications.
Deeks
S G
SG
University of California and San Francisco General Hospital, San Francisco, California, USA. sdeeks@php.ucsf.edu
Grant
R M
RM
D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D012367:RNA, Viral / Q000097:blood; D017211:Treatment Failure; D019562:Viral Load
D017320:HIV Protease Inhibitors; D012367:RNA, Viral